Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 11 formulations under Drugs Prices Control Order (DPCO) – 2013 based on the decision of 89th authority meeting dated June 28, 2021.
The formulations include telmisartan + nebivolol tablet, glimeperide +pioglitazone +metformin HCL (SR) tablet, glimeperide + metformin HCL (SR) tablet, dextromethorphan hydrobromide + chlorpheniramine meleate syrup, esomeprazole & domperidone sustained release capsule, telmisartan + amlodipine + hydrochlorathiazide tablet, vitamin D3 oral drops, paracetamol + methocarbamol + diclofenac potassium tablet.
The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified.
The manufacturers may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price as prescribed by NPPA.
The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price contained in paragraph 11 of the DPCO, 2013.
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
The retail price is applicable only to the individual manufacturer/marketer i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013.
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
